Wedbush maintains Avalo Therapeutics at Outperform, lowers price target to $20 from $22
Wedbush kept Avalo Therapeutics at Outperform but cut its price target to $20 from $22, citing a 9.1% decrease. The new target suggests a 201.7% upside from the Nov 5 close of $6.63. Recent analyst price targets for Avalo range from $10 to $22.
